Literature DB >> 16279293

Liability issues for data monitoring committee members.

David L DeMets1, Thomas R Fleming, Frank Rockhold, Barry Massie, Thomas Merchant, Alan Meisel, Barbara Mishkin, Janet Wittes, David Stump, Robert Califf.   

Abstract

In randomized clinical trials, a data monitoring committee (DMC) is often appointed to review interim data to determine whether there is early convincing evidence of intervention benefit, lack of benefit or harm to study participants. Because DMCs bear serious responsibility for participant safety, their members may be legally liable for their actions. Despite more than three decades of experiences with DMCs, the issues of liability and indemnification have yet to receive appropriate attention from either government or industry sponsors. In industry-sponsored trials, DMC members are usually asked to sign an agreement delineating their responsibilities and operating procedures. While these agreements may include language on indemnification, such language sometimes protects only the sponsor rather than the DMC members. In government-sponsored trials, there has been even less structure, since typically there are no signed agreements regarding DMC activities. This paper discusses these issues and suggests sample language for indemnification agreements to protect DMC members. This type of language should be included in DMC charters and in all consulting agreements signed by DMC members.

Entities:  

Mesh:

Year:  2004        PMID: 16279293     DOI: 10.1191/1740774504cn54oa

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  6 in total

1.  Data Monitoring Committees: Current issues.

Authors:  Thomas R Fleming; Susan S Ellenberg; David L DeMets
Journal:  Clin Trials       Date:  2018-04-09       Impact factor: 2.486

2.  Independent data monitoring committees: preparing a path for the future.

Authors:  Connie N Hess; Matthew T Roe; C Michael Gibson; Robert J Temple; Michael J Pencina; Deborah A Zarin; Kevin J Anstrom; John H Alexander; Rachel E Sherman; Fred T Fiedorek; Kenneth W Mahaffey; Kerry L Lee; Shein-Chung Chow; Paul W Armstrong; Robert M Califf
Journal:  Am Heart J       Date:  2014-05-15       Impact factor: 4.749

3.  Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trials.

Authors:  Thomas R Fleming; Charles H Hennekens; Marc A Pfeffer; David L DeMets
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

4.  Data monitoring committees: Promoting best practices to address emerging challenges.

Authors:  Thomas R Fleming; David L DeMets; Matthew T Roe; Janet Wittes; Karim A Calis; Amit N Vora; Alan Meisel; Raymond P Bain; Marvin A Konstam; Michael J Pencina; David J Gordon; Kenneth W Mahaffey; Charles H Hennekens; James D Neaton; Gail D Pearson; Tomas Lg Andersson; Marc A Pfeffer; Susan S Ellenberg
Journal:  Clin Trials       Date:  2017-02-01       Impact factor: 2.486

5.  Creation of an institutional semi-independent data monitoring committee.

Authors:  Lisa R Tannock; Marietta Barton-Baxter; William W Stoops
Journal:  Clin Trials       Date:  2019-07-01       Impact factor: 2.486

Review 6.  Protecting clinical trial participants and protecting data integrity: are we meeting the challenges?

Authors:  Susan S Ellenberg
Journal:  PLoS Med       Date:  2012-06-12       Impact factor: 11.069

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.